Table 1.
Demographic and clinicopathological data of 55 patients with esophageal GIST
| Parameter | Study cohort of esophageal GIST | ||
|---|---|---|---|
| Age (∑ = 55) | |||
| Mean (yr, ± SD) | 60.3 (11.9) | ||
| Median (yr, range) | 61.0 (21.0; 87.9) | ||
| Sex (∑ = 55) | n | % | |
| Female | 19 | 34.5 | |
| Male | 36 | 65.5 | |
| Localization (∑ = 55) | |||
| Middle 1/3 | 2 | 4.0 | |
| Middle/lower 1/3 | 2 | 4.0 | |
| Lower 1/3 | 46 | 92.0 | |
| Not definable | 5 | - | |
| Tumor size (∑ = 52) | |||
| Mean (cm, ± SD) | 8.0 (4.8) | ||
| Median (cm, range) | 7.35 (0.2; 25.0) | ||
| Mitotic rate (∑ = 41) | |||
| Mean (per 50HPF, ± SD) | 13.4 (18.2) | ||
| Median (per 50HPF, range) | 5.5 (0; 79) | ||
| Risk after Fletcher et al. (∑ = 46) | n | % | |
| High | 25 | 56.8 | |
| Intermediate | 10 | 22.7 | |
| Low | 6 | 13.6 | |
| Very Low | 3 | 6.8 | |
| Operative therapy (∑ = 33) | |||
| Enucleation | 14 | 42.4 | |
| Esophagectomy | 19 | 57.6 | |
| TKI/Imatinib (∑ = 55) | |||
| Yes/No | 6/49 | 10.9/89.1 | |
| Histological subtype (∑ = 43) | |||
| Spindle cell/Epithelioid or mixed | 35/8 | 81.4/18.6 | |
| Immunohistochemistry | pos | neg | |
| (∑ = 53) | c-kit | 53 | 0 |
| (∑ = 46) | CD34 | 45 | 1 |
| (∑ = 22) | Aktin | 7 | 15 |
| (∑ = 10) | Desmin | 4 | 6 |
| (∑ = 4) | Vimentin | 4 | 0 |
| (∑ = 34) | S100 | 0 | 34 |
| Mutational status (∑ = 14) | n | % | |
| c-kit | 8 | 57.1 | |
| PDGFRα | 0 | 0.0 | |
| wild type | 6 | 42.9 | |
| Symptoms | |||
| (∑ = 50) | Symptoms at diagnosis | 38 | 76.0 |
| Incidental | 12 | 24.0 | |
| (∑ = 49) | Dysphagia | 26 | 53 |
| Weight loss | 10 | 20 | |
| Bleeding | 6 | 12 | |
| Abdominal pain | 4 | 8 | |
| Nausea | 3 | 6 | |
| Cough | 3 | 6 | |
| Vomiting/Reflux/Night sweat | 1/1/1 | 2/2/2 | |
| Follow up time | |||
| Mean (m, ± SD)/median (m, range) | 48.2 (46.6)/28.0 (1.9; 202.0) | ||
| Survival rates | % | ||
| 1-/3-/5-year DSS | 97.5/76.3/50.9 | ||
| 1-/3-/5-year DFS | 86.6/65.3/65.3 | ||
| 1-/3-/5-year OS | 95.2/72.4/48.3 | ||
| Survival data | n | % | |
| (∑ = 55) | Recurrence or metastases | 14 | 25.5 |
| (∑ = 55) | Exitus letalis overall | 18 | 32.7 |
| (∑ = 54) | Exitus letalis GIST depend. | 15 | 27.3 |
HPF, high power field; m, month; SD, standard deviation; yr, year; DSS, disease specific survival; DSF, disease free survival; OS, overall survival.